Ellipses Pharma Ltd. has agreed to in-license global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody ...

UK-based Ellipses Pharma, a company progressing cancer treatments through an innovative drug development model, has announced that it is to develop a next-generation immuno-oncology drug which could ...

Ellipses Pharma, a global drug development company based in London, focuses on accelerating the development of cancer medicines and treatments through an innovative drug development model that ...

Ellipses Pharma is taking a different approach. Ellipses, a developer of innovative cancer medicines, has built a cloud-based platform to crowdsource scientific and clinical insight from a large ...

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal with Ellipses Pharma Ltd. for GENA-104, a phase I-ready immuno-oncology asset, ...

Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it is ...

(MENAFN- AETOSWire) (BUSINESS WIRE ) -- Ellipses Pharma Limited ( “ Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an ...